ASH 2025 – Terns wins
The company might have blown Enliven out of the water.
ASH 2025 – J&J’s multiple myeloma juggling act
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
ASH 2025 – Adcetris good, follow-ons not so much
Pfizer reveals the discontinuation of PF-08046044.
ASH 2025 – BeOne pulls away from Nurix
On efficacy, at least, BeOne’s BTK degrader shows an edge.
ASH 2025 – Gilead spills the beans on “fast” Car-T
It’s less about being fast, more about producing a better product.
ASH 2025 – Kura seeks further safety edge
The company will try to get the Komzifti QTc prolongation warning removed.
ASH 2025 – BeOne assuages sonrotoclax safety concerns
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
